|
GSK plc will present 33 abstracts, including four late breakers, at the 2026 American Thoracic Society (ATS) International Conference in Orlando, Florida (15-20 May). GSK’s decades of expertise in respiratory care and deep understanding of patients have developed a portfolio of long-acting biologics and inhaled medicines designed to achieve ambitious treatment goals, such as disease stability, and alleviate patient and health system burden, including improved adherence and fewer hospitalisations.
Two-year efficacy and safety data for depemokimab will show the potential for sustained disease control in just two doses a year with the aim to transform patient and health system outcomes
- Integrated analyses from the pivotal SWIFT-1 and SWIFT-2 trials and open-label AGILE extension study will show long-term sustained efficacy with depemokimab in patients with severe asthma (Presentations #P1396 and #P1391)
- Additional analyses highlighting long-term efficacy and safety in severe asthma patients with comorbid chronic rhinosinusitis with nasal polyps (CRSwNP) (Presentation #520) and irrespective of baseline inhaled corticosteroid dose (Presentation #519) will also be presented
- New patient preference study will show patients prefer twice-yearly dosing and highlights the influence of dosing frequency on adherence (Presentation #P1424)
- • Further analyses examine the association between asthma biologic adherence and improved clinical outcomes in real-world settings (Presentation #P1411 and session C14)
New analyses for mepolizumab in COPD highlight importance and potential to achieve disease stability as an emerging treatment goal
- Analyses from the phase III programme in COPD for mepolizumab will be presented and show, for the first time, the ability of a biologic to achieve disease stability in a wide spectrum of COPD patients (Presentation #P1506)
- Additional analyses looking at the burden of COPD exacerbations and the impact they have on patients and healthcare systems will also be presented, as COPD is projected to be the leading cause of hospital admissions globally over the next decade (Presentation #P1496)
Exdensur is the first ultra-long-acting biologic being evaluated for certain respiratory diseases with underlying type 2 inflammation. It combines high interleukin-5 (IL-5) binding affinity and high potency with an extended half-life to enable twice-yearly dosing. IL-5 is a key cytokine in type 2 inflammation.
Nucala is a monoclonal antibody that targets and binds to interleukin-5 (IL-5), a key messenger protein (cytokine) in type 2 inflammation. It has been developed for the treatment of a range of diseases with underlying type 2 inflammation.
GSK continues to build on decades of pioneering work to deliver more ambitious treatment goals, develop the next generation standard of care, and redefine the future of respiratory medicine for hundreds of millions of people with respiratory diseases. With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics, and inhaled medicines, GSK is focused on improving outcomes and the lives of people living with all types of asthma and COPD, along with less understood refractory chronic cough or rarer conditions like systemic sclerosis with interstitial lung disease. GSK is harnessing the latest science and technology with the aim of modifying the underlying disease dysfunction and preventing progression.
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.
|